Results 51 to 60 of about 3,354,986 (307)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

Journal of Immunology Research, 2019
To improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library.
Weiyi Qiu, Chang Zhang, Shuang Wang, Xiaoyan Yu, Qiong Wang, Dadi Zeng, Peng Du, Jinling Ma, Yiqiong Zheng, Bo Pang, Yunzhou Yu, Feng Long, Xiaobin Pang, Zhiwei Sun   +13 more
doaj   +1 more source

Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences

mAbs, 2020
The ability to genetically encode non-natural amino acids (nnAAs) into proteins offers an expanded tool set for protein engineering. nnAAs containing unique functional moieties have enabled the study of post-translational modifications, protein ...
Gargi Roy, Jason Reier, Andrew Garcia, Tom Martin, Megan Rice, Jihong Wang, Meagan Prophet, Ronald Christie, William Dall’Acqua, Sanjeev Ahuja, Michael A Bowen, Marcello Marelli   +11 more
doaj   +1 more source

A novel built-in adjuvant metallothionein-3 aids protein antigens to induce rapid, robust, and durable immune responses

Frontiers in Immunology, 2022
Adjuvants are crucial components of vaccines that can enhance and modulate antigen-specific immune responses. Herein, we reported for the first time that human metallothionein-3 (MT3), a low molecular weight cysteine-rich metal-binding protein, was a ...
Ying Yin, Yanfei Gu, Xiaodong Zai, Ruihua Li, Xinjie Zhu, Rui Yu, Jun Zhang, Shuyi Wang, Yue Zhang, Jian Lin, Junjie Xu, Wei Chen   +11 more
doaj   +1 more source

Bereavement and marriage are associated with antibody response to influenza vaccination in the elderly [PDF]

, 2006
Stressful life events exposure including bereavement, an event commonly experienced by elderly people, social support, marital status and satisfaction were examined in relation to antibody response to the annual trivalent influenza vaccination in an ...
Aiken, Anna C. Phillips, Bartrop, Bodnar, Bowling, Brown, Burns, Burns, Carroll, Christenfeld, Christopher Ring, Cohen, Coyne, Douglas Carroll, Ford, Freeston, Glaser, Glaser, Glaser, Gluckman, Goodkin, Gordon, Heslop, House, Irwin, John Macleod, Johnson, Kemeny, Kiecolt-Glaser, Kiecolt-Glaser, Kiecolt-Glaser, Kiecolt-Glaser, Kiecolt-Glaser, Kiecolt-Glaser, Kohut, Locke, MacKenzie, Manor, Mark Drayson, Marmot, Miller, Miller, Moynihan, Parkes, Patriarca, Phillips, Phillips, Pressman, Robles, Ross, Schleifer, Sherbourne, Vedhara, Vedhara, Verbrugge, Victoria E. Burns, West, Yang, Zisook   +58 more
core   +1 more source

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists

Nature Communications
The ability to leverage antibodies to agonize disease relevant biological pathways has tremendous potential for clinical investigation. Yet while antibodies have been successful as antagonists, immune mediators, and targeting agents, they are not readily
Matthew G. Romei, Brandon Leonard, Zachary B. Katz, Daniel Le, Yanli Yang, Eric S. Day, Christopher W. Koo, Preeti Sharma, Jack Bevers III, Ingrid Kim, Huiguang Dai, Farzam Farahi, May Lin, Andrey S. Shaw, Gerald Nakamura, Jonathan T. Sockolosky, Greg A. Lazar   +16 more
doaj   +1 more source

No association between islet cell antibodies and coxsackie B, mumps, rubella and cytomegalovirus antibodies in non-diabetic individuals aged 7–19 years [PDF]

, 1991
Viral antibodies were tested in a cohort of 44 isletcell antibody-positive individuals age 7–19 years, and 44 of their islet cell antibody-negative age and sex-matched classmates selected from a population study of 4208 pupils who had been screened for ...
A Tarn, A Toniolo, B. O. Boehm, DK Wagener, E Bonifacio, E. F. Pfeiffer, E. Heinze, EJ Rayfield, G Antoniadis, G Frisk, G Kuglin, H Champsaur, H. Egle, H. Hauner, J Karjalainen, J Seißler, J-W Yoon, J. E. Banatvala, J. Sei�ler, JE Banatvala, K Helmke, KP Ratzmann, M. Gl�ck, ML King, P. Muir, R Gladisch, S Srikanta, T Tuvemo, T Tuvemo, W. A. Scherbaum, W. Hampl, WA Scherbaum, WJ Riley   +32 more
core   +1 more source

Blinatumomab Utilization in Pediatric B‐Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Blinatumomab is a bispecific T‐cell engager approved for the treatment of pediatric B‐cell acute lymphoblastic leukemia (B‐ALL). Outpatient home infusion reduces hospitalization burden and optimizes resource utilization, but is logistically challenging.
Angela Parra del Riego, Kellee Parker, William C. Thomsen, James B. Ford, Mallorie B. Heneghan, David Spencer Mangum, Jennifer L. McNeer, Luke D. Maese, Claire E. F. Miller, Richard Lemons, Taumoha Ghosh   +10 more
wiley   +1 more source

Evaluating pre-treatment methods in the isolation and purification of monoclonal IgG antibody [PDF]

, 2008
In this study, the effects of different sample preparation techniques on the separation of monoclonal antibody IgG I were inve st igated experimentally. Monoclonal IgG I was obtained from hybridoma cell line TB /C3 transfected with bcl-2 carrier plasmid.
Abdul Majid, Fadzilah Adibah, Shian, L. P.   +1 more
core  

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi, Daisuke Katagiri, Takeyuki Watadani, Shunichi Matsuda, Hiroshi Kaneko, Noritoshi Arai   +5 more
wiley   +1 more source

Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment [PDF]

, 2014
The rapidly increasing interest in the synthesis of antibody–drug conjugates as powerful targeted anticancer agents demonstrates the growing appreciation of the power of antibodies and antibody fragments as highly selective targeting moieties.
Boyle, Ross W., Bryden, Francesca, Caddick, Stephen, Chudasama, Vijay, Maruani, Antoine, Savoie, Huguette, Smith, Mark E. B.   +6 more
core   +1 more source